Ingrid Wiik, Chairman of the Board, holds a Master of Pharmacy from University of Oslo, and an M.Sc (Biopharmacy) from University of London, and an MBA from the Norwegian School of Management. She has spent more than 30 years in the pharmaceutical industry, both in R&D and general management, and has extensive leadership and international experience. In the years from 2000 to 2006 she was President and CEO of Alpharma Inc., a NYSE listed US Corporation with $ 1.5 billion in turnover and 4300 employees. Ms. Wiik currently holds several Board positions: Photocure ASA and Algeta ASA.

Gustav Ingemar Kihlström, has a doctorate in physiology from Uppsala University. He is an Associate Professor of Uppsala University and has more than 15 years experience with Astra and Pharmacia in Sweden and other countries. From 1996 to 2004 he worked as a financial analyst, latterly as head of the health sector team at ABG Securities in Stockholm. Today he is an independent consultant within the field of science and the financing of life science companies. He is Chairman of the board of Recopharma AB, Creative Antibiotics AB and Hammercap AB, and a board member of several listed and unlisted companies.

Ulrica Slåne currently holds a position as head of life science investments at AP3, The third National Swedish Pension Fund. She is also at the board of the listed company Karolinska Development, based in Stockholm. Slåne holds a B Sc in Finance and Business Administration from Stockholm School of Economics and has also studied Physiology and Pharmacology at the Karolinska Institute. Prior to her position as fund manager, Slåne spent ten years as a financial analyst for the Life Science sector at various investment banks.

Tom Pike is actively involved with a number of life science companies and organizations in the capacity of consultant and/or board member. His past experience ranges from Chairman & CEO of Clavis Pharma ASA, a public oncology drug development company to Partner of the venture capital group NeoMed Management and more than 18 years’ experience as CEO, sales and marketing director, business alliance manager and other positions at Hoffmann-La Roche in Switzerland and Norway. He has served on the board (past Chairman) of the Norwegian Association of Pharmaceutical Manufacturers for six years. Pike is a Norwegian and British citizen and holds a B.Sc. Honours in Pharmacology.